Benign Evolution of Complex Regional Pain Syndrome (CRPS) Type 1 in Patients Treated with Intravenous Neridronate: A Single-Center Real-Life Experience

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Nov 27

PMID 39598411

Authors

Jacopo Ciaffi

Gianluca Festuccia

Claudio Ripamonti

Luana Mancarella

Veronica Brusi

Federica Pignatti

Lucia Lisi

Lisa Berti

Piero Ruscitti

Cesare Faldini

Francesco Ursini

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the long-term effects of intravenous neridronate treatment in patients with complex regional pain syndrome type 1 (CRPS) in a real-life setting.

Methods: We conducted a retrospective study on consecutive CRPS patients treated at our hospital from February 2018 to July 2023. All were treated within three months of the onset of CRPS symptoms. The Patient-Reported Outcomes Measurement Information System 29-Item Health Profile (PROMIS-29) version 2.1 was administered. The main outcome of interest was the evolution of the PROMIS-29 scores from baseline to the last follow-up visit. Patients were categorized as "complete responders" or "non-complete responders". The association of clinical and demographic variables with a complete response was analyzed using chi-square tests and univariate logistic regression.

Results: Thirty-six patients were included, with a median follow-up time of 4.8 years. A significant improvement was noted in the mean numerical pain rating scale (from 6.4 ± 1.9 to 3.1 ± 2.4, < 0.001), as well as across all PROMIS-29 domains. Physical function improved from 34.2 ± 4.9 to 49.2 ± 9.9, < 0.001; anxiety from 58.0 ± 6.7 to 49.6 ± 6.9, < 0.001; depression from 55.3 ± 6.3 to 47.7 ± 6.6, < 0.001; fatigue from 55.7 ± 7.7 to 50.9 ± 8.7, < 0.001; sleep disturbance from 53.8 ± 6.8 to 51.3 ± 6.6, = 0.034; social roles and activities from 41.8 ± 5.2 to 51.8 ± 8.9, < 0.001; and pain interference from 64.1 ± 5.9 to 52.4 ± 9.9, < 0.001. The likelihood of achieving a complete response was associated with the male sex, foot or ankle injuries (compared to hand and wrist injuries), and a younger age. No association was found with the type of inciting event or with the body mass index.

Conclusions: Our real-life data indicate that early treatment with neridronate leads to substantial benefits in patients affected by CRPS type 1. The strongest responses are seen in young patients, males, and those with lower limb involvement.

References

Varenna M, Zucchi F, Ghiringhelli D, Binelli L, Bevilacqua M, Bettica P . Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol. 2000; 27(6):1477-83. View

Eun Young H, Hyeyun K, Sang Hee I . Pamidronate effect compared with a steroid on complex regional pain syndrome type I: Pilot randomised trial. Neth J Med. 2016; 74(1):30-5. View

Adami G, Fassio A, Rossini M, Montanari F, Manfre S, Bonasera G . Long-term effectiveness and predictors of bisphosphonate treatment in type I complex regional pain syndrome. Clin Exp Rheumatol. 2023; 42(5):961-966. DOI: 10.55563/clinexprheumatol/sdv5qt. View

Rabin R, de Charro F . EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5):337-43. DOI: 10.3109/07853890109002087. View

Grieve S, Perez R, Birklein F, Brunner F, Bruehl S, Harden R . Recommendations for a first Core Outcome Measurement set for complex regional PAin syndrome Clinical sTudies (COMPACT). Pain. 2017; 158(6):1083-1090. PMC: 5438049. DOI: 10.1097/j.pain.0000000000000866. View

Nicholas M . The pain self-efficacy questionnaire: Taking pain into account. Eur J Pain. 2006; 11(2):153-63. DOI: 10.1016/j.ejpain.2005.12.008. View

Bruehl S, Maihofner C, Stanton-Hicks M, Perez R, Vatine J, Brunner F . Complex regional pain syndrome: evidence for warm and cold subtypes in a large prospective clinical sample. Pain. 2016; 157(8):1674-81. DOI: 10.1097/j.pain.0000000000000569. View

Rogers T, Holen I . Tumour macrophages as potential targets of bisphosphonates. J Transl Med. 2011; 9:177. PMC: 3215187. DOI: 10.1186/1479-5876-9-177. View

Borchers A, Gershwin M . Complex regional pain syndrome: a comprehensive and critical review. Autoimmun Rev. 2013; 13(3):242-65. DOI: 10.1016/j.autrev.2013.10.006. View

10.

Marinus J, Moseley G, Birklein F, Baron R, Maihofner C, Kingery W . Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 2011; 10(7):637-48. PMC: 5511749. DOI: 10.1016/S1474-4422(11)70106-5. View

11.

Varenna M, Manara M, Rovelli F, Zucchi F, Sinigaglia L . Predictors of Responsiveness to Bisphosphonate Treatment in Patients with Complex Regional Pain Syndrome Type I: A Retrospective Chart Analysis. Pain Med. 2016; 18(6):1131-1138. DOI: 10.1093/pm/pnw207. View

12.

Baronio M, Sadia H, Paolacci S, Prestamburgo D, Miotti D, Guardamagna V . Molecular Aspects of Regional Pain Syndrome. Pain Res Manag. 2020; 2020:7697214. PMC: 7171689. DOI: 10.1155/2020/7697214. View

13.

Moreau M, Guillet C, Massin P, Chevalier S, Gascan H, Basle M . Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol. 2006; 73(5):718-23. DOI: 10.1016/j.bcp.2006.09.031. View

14.

Jamroz A, Berger M, Winston P . Prednisone for Acute Complex Regional Pain Syndrome: A Retrospective Cohort Study. Pain Res Manag. 2020; 2020:8182569. PMC: 7060858. DOI: 10.1155/2020/8182569. View

15.

Vijayakumar G, Blank A . Patient-reported outcome tools in musculoskeletal oncology. J Surg Oncol. 2023; 128(3):418-424. DOI: 10.1002/jso.27386. View

16.

Kalita J, Pandey P, Shukla R, Misra U . Prednisolone 20 mg vs 40 mg in complex regional pain syndrome type I: A randomized controlled trial. J Clin Neurosci. 2023; 113:108-113. DOI: 10.1016/j.jocn.2023.05.017. View

17.

Tang C, Sookochoff M, Rhea L, Carrier J, Prather H, Guan L . An audit of structure-based medical acupuncture by a single provider in patients with musculoskeletal pain using PROMIS scores as the outcome. Acupunct Med. 2022; 41(1):48-54. DOI: 10.1177/09645284221118589. View

18.

Carr E, De La Cerda A, Fiala K . Complex regional pain syndrome. Proc (Bayl Univ Med Cent). 2016; 29(3):333-4. PMC: 4900790. DOI: 10.1080/08998280.2016.11929460. View

19.

Chiarotto A, Vanti C, Ostelo R, Ferrari S, Tedesco G, Rocca B . The Pain Self-Efficacy Questionnaire: Cross-Cultural Adaptation into Italian and Assessment of Its Measurement Properties. Pain Pract. 2014; 15(8):738-47. DOI: 10.1111/papr.12242. View

20.

Finch A, Meregaglia M, Ciani O, Roudijk B, Jommi C . An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Soc Sci Med. 2021; 292:114519. DOI: 10.1016/j.socscimed.2021.114519. View